A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

NCT06901349 · Withdrawn

Last updated 2026-05-28

This clinical trial is testing the effects of bimagrumab and tirzepatide, alone or together, on body weight in adults with obesity or overweight who also have type 2 diabetes.

Status Withdrawn Stopped before any participant enrolled.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Who can join Ages 18–75 · all sexes

Timeline Started 2025-05 · est. completion 2025-06

Where 50 sites · Argentina, Canada, China, Japan, United States

What this study is testing ClinicalTrials.gov NCT06901349 ↗

Description as written by the study sponsor.

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

Treatments tested

Bimagrumab also known as LY3985863 Drug

Administered SC
Tirzepatide also known as LY3298176 Drug

Administered SC
Bimagrumab Placebo Drug

Administered SC
Tirzepatide Placebo Drug

Administered SC

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06901349 ↗